Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
127 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Endometriosis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Endometriosis - Pipeline Review, H1 2015', provides an overview of the Endometriosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Endometriosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Endometriosis Overview 11 Therapeutics Development 12 Pipeline Products for Endometriosis - Overview 12 Pipeline Products for Endometriosis - Comparative Analysis 13 Endometriosis - Therapeutics under Development by Companies 14 Endometriosis - Therapeutics under Investigation by Universities/Institutes 17 Endometriosis - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Endometriosis - Products under Development by Companies 22 Endometriosis - Products under Investigation by Universities/Institutes 24 Endometriosis - Companies Involved in Therapeutics Development 25 AbbVie Inc. 25 Addex Therapeutics Ltd 26 APAvadis Biotechnologies Srl 27 Astellas Pharma Inc. 28 Bayer AG 29 Dongkook Pharmaceutical Co., Ltd. 30 ElexoPharm GmbH 31 EndoCeutics, Inc. 32 Euroscreen S.A. 33 Evotec AG 34 Forendo Pharma Oy 35 GlaxoSmithKline plc 36 Isifer AB 37 Kissei Pharmaceutical Co., Ltd. 38 Lipicard Technologies Limited 39 Neurocrine Biosciences, Inc. 40 Orphagen Pharmaceuticals, Inc. 41 Philogen S.p.A. 42 PregLem SA 43 Repros Therapeutics Inc. 44 SK Chemicals Co., Ltd. 45 Takeda Pharmaceutical Company Limited 46 ValiRx Plc 47 Endometriosis - Therapeutics Assessment 48 Assessment by Monotherapy Products 48 Assessment by Combination Products 49 Assessment by Target 50 Assessment by Mechanism of Action 52 Assessment by Route of Administration 54 Assessment by Molecule Type 56 Drug Profiles 58 (anastrozole + levonorgestrel) - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 acolbifene hydrochloride + GnRH agonist + prasterone - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ADX-68692 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ASP-1707 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BAY-1026153 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BAY-1128688 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 bentamapimod - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Drug to Target RERG for Endometriosis - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Drugs for Endometriosis - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 elagolix sodium - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Endole - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 epelsiban besylate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ESN-364 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 EVE-104 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 F8IL-4 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 FP-5677 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 goserelin biosimilar - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 KLH-2109 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 LT-6121 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 NCE-403 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Peptides for Cancer and Endometriosis - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Peptides to Inhibit Aminopeptidase A for Cancer and Endometriosis - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 PGL-2001 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 relugolix - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecule to Antagonize GnRH for Endometriosis, Uterine Fibroids, and Oncology - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 SR-16234 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 telapristone acetate - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 triptorelin pamoate biosimilar - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 VAL-201 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 vilaprisan - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 VPE-001 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Endometriosis - Recent Pipeline Updates 105 Endometriosis - Dormant Projects 118 Endometriosis - Discontinued Products 120 Endometriosis - Product Development Milestones 121 Featured News & Press Releases 121 Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 121 Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 121 Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 121 Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 122 Apr 25, 2013: ValiRx Receives Australian Patent For VAL201 123 Nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 123 Oct 08, 2012: Repros Therapeutics's Proellex Receives FDA Acceptance For Reclassification Of Clinical Hold Status 123 Aug 27, 2012: FDA Provides Recommendations For Phase II Protocol For Repros' Proellex In Treatment Of Endometriosis 124 Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 125 Jul 16, 2012: FDA Provides Guidance To Repros For Conducting Phase II Study Of Proellex In Treatment Of Endometriosis 125 Appendix 126 Methodology 126 Coverage 126 Secondary Research 126 Primary Research 126 Expert Panel Validation 126 Contact Us 127 Disclaimer 127
List of Tables Number of Products under Development for Endometriosis, H1 2015 12 Number of Products under Development for Endometriosis - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Comparative Analysis by Unknown Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Investigation by Universities/Institutes, H1 2015 24 Endometriosis - Pipeline by AbbVie Inc., H1 2015 25 Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2015 26 Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2015 27 Endometriosis - Pipeline by Astellas Pharma Inc., H1 2015 28 Endometriosis - Pipeline by Bayer AG, H1 2015 29 Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2015 30 Endometriosis - Pipeline by ElexoPharm GmbH, H1 2015 31 Endometriosis - Pipeline by EndoCeutics, Inc., H1 2015 32 Endometriosis - Pipeline by Euroscreen S.A., H1 2015 33 Endometriosis - Pipeline by Evotec AG, H1 2015 34 Endometriosis - Pipeline by Forendo Pharma Oy, H1 2015 35 Endometriosis - Pipeline by GlaxoSmithKline plc, H1 2015 36 Endometriosis - Pipeline by Isifer AB, H1 2015 37 Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 38 Endometriosis - Pipeline by Lipicard Technologies Limited, H1 2015 39 Endometriosis - Pipeline by Neurocrine Biosciences, Inc., H1 2015 40 Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2015 41 Endometriosis - Pipeline by Philogen S.p.A., H1 2015 42 Endometriosis - Pipeline by PregLem SA, H1 2015 43 Endometriosis - Pipeline by Repros Therapeutics Inc., H1 2015 44 Endometriosis - Pipeline by SK Chemicals Co., Ltd., H1 2015 45 Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 46 Endometriosis - Pipeline by ValiRx Plc, H1 2015 47 Assessment by Monotherapy Products, H1 2015 48 Assessment by Combination Products, H1 2015 49 Number of Products by Stage and Target, H1 2015 51 Number of Products by Stage and Mechanism of Action, H1 2015 53 Number of Products by Stage and Route of Administration, H1 2015 55 Number of Products by Stage and Molecule Type, H1 2015 57 Endometriosis Therapeutics - Recent Pipeline Updates, H1 2015 105 Endometriosis - Dormant Projects, H1 2015 118 Endometriosis - Dormant Projects (Contd..1), H1 2015 119 Endometriosis - Discontinued Products, H1 2015 120
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
